Novo Nordisk A/S (NYSE:NVO) Shares Sold by American Trust

American Trust decreased its position in Novo Nordisk A/S (NYSE:NVO) by 12.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,350 shares of the company’s stock after selling 786 shares during the quarter. American Trust’s holdings in Novo Nordisk A/S were worth $687,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. First PREMIER Bank acquired a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $25,000. CNB Bank acquired a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $26,000. Dixon Mitchell Investment Counsel Inc. bought a new stake in shares of Novo Nordisk A/S during the first quarter worth $26,000. Orion Capital Management LLC acquired a new position in Novo Nordisk A/S in the 1st quarter worth $26,000. Finally, Frank Rimerman Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $30,000. 11.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

NVO has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, July 1st. Argus increased their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. The Goldman Sachs Group initiated coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective for the company. Finally, BMO Capital Markets reissued an “outperform” rating and set a $163.00 target price on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded down $4.97 during trading on Friday, reaching $127.49. The company had a trading volume of 4,774,033 shares, compared to its average volume of 3,918,008. The firm has a market capitalization of $572.12 billion, a price-to-earnings ratio of 43.96, a price-to-earnings-growth ratio of 1.33 and a beta of 0.41. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The firm’s 50-day simple moving average is $138.21 and its 200 day simple moving average is $129.20. Novo Nordisk A/S has a 52 week low of $78.19 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.06. The firm had revenue of $9.52 billion during the quarter, compared to analysts’ expectations of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.